Depression Clinical Trial
— LYMPHODEPOfficial title:
Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants
Objectives: To identify in patients with major depression different peripheral markers of neuroinflammation in relation to affective symptoms (anxiety, depression, irritability), fatigue and cognitive symptoms; and its relationship with the response to antidepressant treatment with selective serotonin reuptake inhibitors (SSRIs). Methodology: This is a prospective observational cohort study in patients with major depression naturally subjected to treatment with SSRIs. For this, 30 patients with major depression attended in the Outpatient Psychiatry Consultations will be selected. All of them will be evaluated at baseline and after 3 months of treatment, collecting demographic and clinical variables, Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) psychiatric diagnoses, psychopathological scales and immunological and biochemical variables. The correlation between immunological markers and affective and cognitive symptoms at baseline, as well as their variation with treatment, will be analyzed. A group of 20 healthy subjects will be used as a control group. Subsequently, a bivariate comparative analysis will be carried out, where the statistically significant or marginally significant variables associated with psychopathological variables will be used to build a multivariate binary logistic regression model.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | July 31, 2027 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Age between 18 and 65 years - Clinical diagnosis of major depression according to DSM-5 criteria made by a psychiatrist applying the Structured Clinical Interview for DSM-5 (SCID-5). - Eligible for receiving antidepressant treatment for major depression. Exclusion Criteria: - Who have received antidepressant, antipsychotic or euthymizer treatments in the 6 weeks prior to inclusion in the study. - Who present concurrent psychotic symptoms. - Who present disorders due to alcohol or drug use, with active consumption during the last 3 months. - Pregnant women. - Who have serious or unstable medical disorders, Addison's or Cushing's disease, systemic inflammatory or autoimmune diseases, or primary or secondary immunodeficiencies. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitari Germans Trias i Pujol | Badalona | Catalonia |
Lead Sponsor | Collaborator |
---|---|
Germans Trias i Pujol Hospital |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Treatment Response | The response to treatment will be assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS) scale scores. The MADRS scoring instructions indicate that a total score ranging from 0 to 6 indicates that the patient is in the normal range (no depression), a score ranging from 7 to 19 indicates "mild depression", 20 to 34 indicates "moderate depression", a score of 35 and greater indicates "severe depression", and a total score of 60 or greater indicates "very severe depression". | 3 months | |
Secondary | Lymphocyte subpopulations | For the study of lymphocyte subpopulations, a multidimensional flow cytometry panel has been designed. The panel includes markers for the identification of the most representative subpopulations of T cells (Th1, Th2, Th17, Th1/17, Treg, naïve cells, central memory and effector memory, total Tfh, T?d1, T?d2, T?d17, T?d1/17...) and monocytes as well as activation markers (HLADR, CD38), inhibitory checkpoints (PD1, TIM3) and markers of tissue migration and response to chemokines (CCR2, CX3CR1, CXCR6). The results of expression markers and subpopulations will be expressed as percentage over total lymphocyte counts. | 3 years | |
Secondary | Biochemical variables | From the serum samples, the analysis of C-reactive protein and immunoglobulins will be performed by Chemiluminescence immunoassay and expressed in mg/dl. The study of pro-inflammatory and anti-inflammatory cytokines (IL-1, IL-6, Tumor Necrosis Factor (TNF)-a, Interleukin (IL)-12, IL-23, IL-17, IL-22, TGFbeta, IL-10, IL-4) and neurogenesis/neuroinflammation factors (BDNF, VILIP-1, ß-Nerve Growth Factor (NGF), sRAGE, chemokine C-X3-C motif ligand 1 (CX3CL1), Soluble triggering receptor expressed on myeloid cell-2 (sTREM-2)) in serum using Multiplex Bead-based Immunoassay technology and expressed in pg/ml. The study of the relative expression of miRNAs (miR-155, miR-126, miR-223, miR-146a, miR-21, miR-124) will also be carried out from serum samples using real time quantitative PCR (RT-qPCR). | 3 years | |
Secondary | Single-cell CITEseq | Frozen samples will be used to perform lymphocyte transcriptomic and proteomic study at the single cell level, allowing the study of the immune system in great depth. For this, Single cell RNA sequencing technology (CITEseq) will be used. CITEseq is a multimodal single-cell phenotyping method that uses antibody-bound oligonucleotides that act as synthetic transcripts that are captured during single-cell RNA-seq library preparation protocols. This allows immunophenotyping of cells with a potentially unlimited number of markers and analysis of the transcriptome using single-cell sequencing approaches such as those developed by 10x Genomics. | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |